Baidu
map

BMJ:什么才是乳腺癌患者术后淋巴水肿的更佳保守干预措施?

2017-06-13 陶白 肿瘤资讯

淋巴水肿是乳腺癌术后的常见并发症,但外科干预措施应用并不广泛,且仅作为重症淋巴水肿的治疗手段,因此临床上常使用保守干预措施。那么,最佳保守干预措施是什么?近期,荷兰癌症研究所理疗科的临诊流行病学家Martijn M Stuiver副教授发表在《BMJ》杂志上的一项研究对此进行了综述。

淋巴水肿是乳腺癌术后的常见并发症,但外科干预措施应用并不广泛,且仅作为重症淋巴水肿的治疗手段,因此临床上常使用保守干预措施。那么,最佳保守干预措施是什么?近期,荷兰癌症研究所理疗科的临诊流行病学家Martijn M Stuiver副教授发表在《BMJ》杂志上的一项研究对此进行了综述。

淋巴水肿是联合或不联合癌症辅助治疗的乳腺癌手术的常见并发症。腋窝淋巴结清扫术后,常发生因淋巴系统损伤而造成流体聚集。肿胀常发生在手臂,但可累及胸部或背部,并造成疼痛、功能障碍和体像障碍。

近1/5女性乳腺癌幸存者在确诊或手术后的2年发生淋巴水肿,且发生率逐年增加。近年来,前哨淋巴结活检已经作为标准方法进行实施,并普遍降低了淋巴水肿发生率。这意味着,淋巴结临床阳性的女性可进行高风险的腋窝淋巴结清扫术,但是其他女性可不使用该方法。

淋巴水肿虽然可以管理,并可能预防,但不能完全治愈。图1和表1列出了临床实践中常用的预防和治疗淋巴水肿的非手术策略(这些策略常同时使用)。本文讨论了乳腺癌治疗后,这些策略有效性的不确定性。

减充血淋巴疗法为淋巴水肿治疗的基础。该治疗分为两个阶段:持续2~4周的降低期以降低淋巴水肿,之后是维持期防止复发。治疗由人工淋巴引流、加压捆绑、运动、降低期教育、维持期穿戴紧身服装组成。临床中,这些减充血淋巴疗法各阶段的治疗组合差异很大。这些疗法常一起使用,但是其相对有效性存在不确定性。

不确定性的证据是什么?

3项Cochrane系统回顾检测了保守干预措施预防或治疗乳腺癌术后淋巴水肿的有效性。由于试验样本量小,并具有矛盾的结果,因此这些系统回顾缺乏强烈证据。此外,应该单独评估一些干预的有效性(如袜子的压缩等级、人工淋巴引流的频率),并且不同类型的干预措施应相辅相成(如加压和运动)。

预防

最小化发生淋巴水肿风险的连续治疗包括教育、监测、早期干预、运动、人工淋巴引流、通过捆绑或弹力袜进行加压治疗。2015年进行的Cochrane系统回顾(纳入了10项随机对照试验,包括1205例患者)评估了这些方法单独使用或联合使用在预防淋巴水肿中的有效性,并与不干预或每种干预措施进行了对比。该系统回顾纳入的研究是异质性的,一些研究缺乏检测淋巴水肿是否已被预防的效力。只有进行两项等效性研究(358例患者)的Meta分析来确定渐进抗阻运动训练的安全性是可行的。中等质量证据表明,与不锻炼相比,渐进抗阻运动训练不会增加淋巴水肿风险,甚至可以降低该风险(相对风险,0.58;95% CI,0.30~1.13;P=0.11)。

研究的样本量小,以及存在临床和统计学异质性,意味着对临床实践提供建议的证据不充分。此外,这些干预措施会对患者造成不适或产生依赖,并有较高的成本。

治疗

2004年进行的一项Cochrane系统回顾(3项随机对照试验,150例患者)评估了诸如人工淋巴引流、按摩、捆绑、压缩套筒等物理治疗,在降低或控制肢端淋巴水肿上的有效性。试验纳入了不同的治疗组合,但是试验样本量太小以至于不能得出明确结论。

2015年进行的一项Cochrane系统回顾(6项随机对照试验,208例患者)评估了与其他疗法单独使用相比,人工淋巴引流和其他疗法组合在乳腺癌术后淋巴水肿治疗上的有效性。研究结果表明,加压捆绑的强化疗程可降低淋巴水肿体积。1年的随访结果表明,使用弹力袜的患者,一直保持了肢端淋巴水肿体积的降低。当与加压捆绑联合使用时,人工淋巴引流会带来额外获益(手臂淋巴水肿体积降低的平均差,7%;95% CI,1.75~12.47;P=0.009)。两项研究的个体患者数据的组合分析表明,该获益在轻度至中度淋巴水肿的患者亚组中出现。但是,试验样本量小,参与者人数范围从24例~45例,并且较宽的可信区间造成了结果的不确定性。试验未提供不良反应、患者偏好和干预措施成本的信息。两项系统回顾的作者都得出结论,需要良好设计的大型随机试验来提供清晰的建议。

正在进行的研究可能提供相关证据吗?

正在进行的研究可以提供进一步证据,尤其是亚临床淋巴水肿早期干预预防临床淋巴水肿的有效性。进一步的研究可评估人工淋巴引流在预防和治疗上的附加价值,以及淋巴水肿治疗的最佳加压策略。Martijn M Stuiver在2017年2月检索了世界卫生组织临床试验注册,检索内容为乳腺癌相关淋巴水肿的预防和治疗的研究。

Martijn M Stuiver鉴别出5项试验预防淋巴水肿。两项研究调查了抗阻运动和物理治疗与常规治疗相比的有效性。剩下的研究是否已经开始是未知的。

Martijn M Stuiver鉴别出16项正在进行的关于乳腺癌相关淋巴水肿的研究,其中的3项检测了人工淋巴引流与不同形式加压治疗或不同运动方式相比的附加有效性,也研究了激光治疗、瑜伽或中医(针灸)的有效性。虽然一些研究具有大型的目标样本量,但是其中的9项研究的目标样本量<50,从而限制了结果的可靠性。

自从上述Cochrane回顾发表以来,也发表过额外的相关研究。这些新研究和正在进行的研究的预期结果,都强调了将来更新现有系统回顾的重要性。

针对该不确定性我们可以做什么?

对于希望改变淋巴水肿风险因素的患者,如高BMI和静止不动的患者,我们应该对他们进行教育和提供帮助。有关其他防范行为的证据不充分,如避免在手术侧的手臂抽血和注射,但是这些防范行为具有优点,尤其是具有较高淋巴水肿风险的个体。

直到现在,淋巴水肿和具有淋巴水肿风险患者中,抗阻运动安全性的结论尚存矛盾。现有证据表明,抗阻运动不会增加淋巴水肿风险,对于已有淋巴水肿的患者,抗阻运动是安全和获益的。应鼓励乳腺癌存活者定期进行该项干预。

美国国家淋巴水肿网发布的专家共识指南建议,患者应该监测早期症状,如肿胀、感觉沉重或皮肤紧张,如果症状不消退,应咨询专家。

一旦发生症状,推荐专业的淋巴水肿专家进行及时治疗。与国际最佳实践建议一致,治疗应至少包括加压治疗和锻炼。初始治疗后,应使用弹力袜来预防肿胀的发生。考虑到疾病的长期本质,对疾病的教育和优化自我管理实践将成为治疗的组成部分

原始出处:

Martijn M Stuiver. Which are the best conservative interventions for lymphoedema after breast cancer surgery? BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2330 (Published 01 June 2017)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2021-07-17 ms7000001545020091

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2018-02-25 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-16 chunjianf

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-15 小华子
  8. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-15 ylzr123

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 luominglian113

    学习了,谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1000461, encodeId=52111000461c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43715534858, createdName=ms7000001545020091, createdTime=Sat Jul 17 21:44:35 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634529, encodeId=c9e11634529a8, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Sun Nov 12 03:34:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848326, encodeId=553e1848326fd, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 25 06:34:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211318, encodeId=8cad211318da, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRk75KAEKrLGic0S0IvH1aNynsEFQWiaNKdtzvtwj2kafCoPg2icYVbrfBCFiaS74X1uEiaaTTY1H9Xyem/0, createdBy=cec11614828, createdName=chunjianf, createdTime=Fri Jun 16 06:02:03 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571041, encodeId=607215e10413e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366593, encodeId=9362136659321, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333361, encodeId=a4ef1333361d6, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Thu Jun 15 14:34:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211054, encodeId=e876211054de, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 15 09:07:08 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210769, encodeId=dec9210e6980, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 14 19:46:10 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210694, encodeId=5abc210694ca, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:38:06 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 Y—xianghai

    学习了新知识

    0

相关资讯

Oncogenesis:科学家发现抑制乳腺癌肿瘤生长的神奇蛋白质

伯明翰大学的研究人员发现,一种蛋白质可以抑制乳腺癌肿瘤的生长。 最新研究表明脯氨酸富集同源异型域蛋白(PRH)在乳腺癌肿瘤发展中发挥的作用,进而有助于更好地确定患者的预后效果。

SCI REP:TRPC5诱导的自噬通过CaMKKβ/AMPKα/ mTOR途径促进乳腺癌中的耐药性

阿霉素是一种针对癌症的一线化疗药物,但抗药性的发展已成为一个主要问题。虽然自噬被认为是对化学疗法的适应性生存反应,并且可能与化学耐药性相关,但其诱导剂和潜在的分子机制仍不清楚。在这项研究中,我们证明阿霉素上调了TRPC5的表达和自噬的水平,并且,在乳腺癌细胞中,自噬的增加是由TRPC5介导的。

J Women Health:2型糖尿病患者服用低剂量阿司匹林的神奇效果

近日,《女性健康》杂志上刊登了一篇标题为《低剂量的阿司匹林可以减少糖尿病女性患乳腺癌风险》的文章,这是一份来自台湾中山医学院的研究人员进行的一次回顾性研究结果报告。

JCO:晚期乳腺癌的患者的治疗--氟维司群+Abemaciclib,有效且安全(MONARCH 2研究)

MONARCH 2临床试验旨在对比 Abemaciclib 联合氟维司群与安慰剂联合氟维司群用于治疗激素受体阳性(HR+)、人体表皮生长因子受体2-阴性(HER2-)的局部晚期或转移性乳腺癌的治疗效果。Abemaciclib是一种选择性细胞周期蛋白依赖性激酶(CDK)4/6抑制剂。MONARCH 2是一个全球性的、双盲的III期临床试验,患者均为激素受体阳性(HR+)、人体表皮生长因子受体2-阴性

Oncogenesis:科学家发现抑制肿瘤生长的神奇蛋白质

伯明翰大学的研究人员发现,一种蛋白质可以抑制乳腺癌肿瘤的生长。今天发表在《肿瘤起源》上的这项研究,研究了脯氨酸富集同源异型域蛋白(PRH)在乳腺癌肿瘤发展中发挥的作用,进而有助于更好地确定患者的预后效果。伯明翰大学癌症与基因组学研究所的 Padma Sheela Jayaraman 博士说:“PRH 是一种控制和调节基因何时开启或关闭的蛋白质。”“然而,在我们的研究之前,这种蛋白质在乳腺癌中的作用

Science Translational Medicine-双拳出击-免疫检查点抑制治疗乳腺癌取得突破进展

免疫检查点抑制疗法作为一种新型的癌症治疗方法,对多种癌症有着显着的疗效。但是目前为止,并没有在乳腺癌领域取得显着的成效。近日,发表在《科学》杂志子刊 Science Translational Medicine上的封面文章采取新的组合疗法策略,对抑制肿瘤生长,提高小鼠生存率有明显作用。

Baidu
map
Baidu
map
Baidu
map